reason report
world catch upzeal tigit pvrig initi
cgen op
bottom line tigit pvrig could next evolut immun
checkpoint blockad valu compugen perspect
co-discov pathway although anti-tigit landscap
becom increasingli crowd compugen pursu uniqu strategi
inspir decade-long work axi signal
block tigit pvrig relat immun checkpoint receptor
signal parallel compani hypothesi import
target pvrig certain indic proven correct compugen would
enviabl posit pvrig program clinic
develop initi coverag cgen outperform rate
price target
compugen scarciti valu smid compani
activ pvrig/tigit program gener clinic data data
anti-pvrig present modest
promis smid competitor major catalyst class
horizon credibl press report area believ
 premium warrant valuat pleas see companion
note axi includ pvrig tigit addit
analysi scienc clinic progress competit
lean oper structur strong cash balanc provid
good runway compugen well capit come recent
financ fund estim suffici support oper
risk valuat
near-term readout roch disappoint investor
enthusiasm tigit pvrig like diminish
compugen asset could sub-par efficaci
safeti profil rel competit program fc-
fcr engag prove benefici efficaci human
compugen choic backbon anti-
tigit poor one dual pvrig tigit antagon
may prove insuffici unnecessari especi tigit
absenc partner acquir compugen could
struggl complet clinic deep-pocket rival
multi-year clinic lead
blend dcf multipl
ionian simul revenu
net debt total capit
year price history/av daili volume mil cgen
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
world catch upzeal tigit pvrig
initi compugen cgen outperform rate price target
eq
estim
compugen cgen clinic stage immuno-
oncolog io compani built proprietari
compugen discov pvrig co-discov
tigit emerg immun checkpoint
heavi scrutini potenti extend
reach blockad cancer
lead intern program includ
antibodi pvrig
antibodi tigit
establish partnership astrazeneca bayer
valid platform
one pure-play tigit-target
arena asset wholly-own
believ compugen could radar
dose-escal data
june data solid tumor
random cityscap trial
tiragolumab ii roch
preliminari random data
nsclc non-smal cell lung cancer colorect cancer mss microsatellit stabl astrazeneca azn op andi beren bayer bayri cover cover
roch rhhbi cover op geoff porg
compugen antibody-driven io focus pipelin
major catalyst year come competitor data
importantli roch tiragolumab
compugen found provid comput discoveri servic
evolv intern drug develop
like name impli compugen found commerci comput drug discoveri platform
licens tool life scienc compani
novarti abbott account half compugen revenu
compugen shift focu appli proprietari algorithm discov novel therapeut diagnost includ
tigit pvrig
last ten year compugen built wet-lab clinic capabl support research develop
compani file novarti nv cover abbott mp daniel antalffi
compugen stand three decad comput experi
recent pivot drug develop
major landmark histori compugen
found israel
start sell hardwar softwar system acceler homolog search biolog sequenc
began develop lead comput biolog platform
biolog laboratori establish valid comput predict
went public nasdaq
went public tel aviv stock exchang
shift focu discoveri base collabor intern develop therapeut protein diagnost
publish initi find tigit shortli genentech
enter research collabor bayer
disclos valid data pvrig antibodi block interact ligand
present data character pvrig identifi lead antibodi program
identifi lead anti-tigit candid
clinic trial collabor enter
enter clinic bayer direct
initi data phase studi present
biggest breakthrough come compugen in-silico platform sinc cgen pivot immuno-
oncolog primari area studi conserv gene structur protein combin
character express across tissu
pharma partnership provid valid support pipelin
collabor licens
agreement develop
two target identifi
current
cgen receiv
up-front mileston
payment deal
elig receiv
bayer return right anoth
exclus right bi-specif
multi-specif antibodi
azn sole respons
develop
elig receiv
mileston first
current statu product
deal disclos
agreement provid
opdivo nivolumab
evalu compugen
trial
also suppli opdivo
anti-tigit
cgen upcom triplet
studi
deal made
equiti invest
develop broader tigit space largest influenc
cgen share
steadi rise
phase data progress
earli build-up roch
signal interest tigit
target axi
pvrig tigit
signal pvr-nectin famili axi import role
regul immun system chronic set includ cancer
overview pvr-nectin famili axi signal
antigen-pres cell apc tumor cell
regul nk cell axi
tigit pvrig checkpoint inhibit
anti-canc immun multipl
mechan includ inhibit co-
pvr ligand express high
level numer cancer includ tumor
respons resist antagon
compugen focu pvrig blockad separ
competit
compani clinic pvrig antagonist
hypothes antagon pvrig
tigit well maxim benefit
select indic
companion note detail
mechanist competit assess
murter et al johnston et al chiang et al levi et al illustr jeremi cook
tigit landscap crowd larg small competitor
excit build ahead random data roch
shade compani
also track preclin program includ bispecif note vibostolimab tiragolumab umbrella trial design
 rotat therapi data expect earlier note initi public edit content fix error multipl myeloma melanoma
therapi includ merck clinicaltri gov svb leerink immuno-oncolog industri analyt ionian databas
drug nameprimari sponsortri phasencttri namestatu start dateprimari end datepati trialtreatmentcanc settingtreat mechanismfc-fcr /- zimberelimabsolid tumorstigit antagonist antagonist zimberelimab /- nsclc antagonist antagonist /- /- pembrolizumabsolid tumorstigit antagonist /- antagonist tislelizumab solid tumorstigit antagonist antagonist /- nivolumabsolid tumorstigit antagonist /- antagonist yet /- pomalidomid multipl myelomatigit antagonist /- imid /- nivolumabsolid tumorspvrig antagonist /- yet nivolumab tumorspvrig antagonist antagonist tigit tumor hemetigit tumorstigit yet /- sintilimabsolid tumor hemetigit antagonist /- antagonist vibostolimabmerck coph /- pembrolizumab co-formul vibostolimab pembrolizumab /- chemosolid tumorstigit antagonist /- antagonist /- chemotherapyyesvibostolimabmerck coph pembrolizumab nsclctigit antagonist antagonist chemotherapyyesvibostolimabmerck coph yet melanomatigit antagonist antagonistyesvibostolimabmerck coph yet pembrolizumab melanomatigit antagonist antagonist antagonistyesvibostolimabmerck coph yet pembrolizumabneoadj melanomatigit antagonist antagonistyestiragolumabrocheph /- atezolizumab /- chemosolid tumorstigit antagonist /- antagonist /- chemotherapi yestiragolumabrocheph atezolizumab pancreatictigit antagonist antagonist chemotherapi yestiragolumabrocheph esophag atezolizumab /- esophag tigit antagonist antagonist /-chemotherapi yestiragolumabrocheph nsclctigit antagonist antagonistyestiragolumabrocheph atezolizumab bladdertigit antagonist antagonist yestiragolumabrocheph /- rituximab /- dlbcl fl mmtigit antagonist /- mab /- mabyestiragolumabrocheph atezolizumab sclctigit antagonist antagonist chemotherapyyestiragolumabrocheph nsclc antagonist antagonistyestiragolumabrocheph yet atezolizumab cervic antagonist antagonistyessgn-tgtseattl geneticsph yet /- tumorstigit antagonist /- antagonisty compugen ltd
current excit tigit contrast modest clinic benefit
report thu far support roch enthusiasm
comparison avail tigit/pvrig clinic data
discontinu due ae
studi
progress
owner mereo
plan advanc look
partner
set start next half
teae treatment-emerg advers event deem relat treatment investig
compugen data well receiv earli sign clinic
benefit difficult treat patient popul
safeti
identifi
dlt treatment-rel
gr teae rate
may fit futur schedul
pr
evid activ without optim
respond platinum
dose limit follow-up
mss-crc patient five stabl
resist median prior line
chemo io-nav
respons observ sub-
partial respons durabl on-going
primari periton cancer
close relat ovarian
cancer tumor overexpress
pr
respons observ earli dose-
respons durabl on-going
limit follow-up respons
seen higher dose
nine patient studi
previous progress checkpoint
six sd
respond io-nav
dose-relationship establish
compugen trial strategi establish safeti efficaci block
pvrig addit benefit triplet blockad pvrig tigit
expans cohort tumor high
breastand mss-colorect five
sd seen dose escal
dlt establish mg/kg
pr orr sd dcr
enrol complet expect year
dose escal opdivo dose fix
pr orr sd dcr
dlt observ mg/kg
paus focu triplet phase
dose escal opdivo bms-
expans cohort tumor high
tumor-agnost high
tumor select low express
rel typic respons
singl agent may disentangl
contribut dual pvrig/tigit
antagon
dcf/multipl blend part sotp valuat
 specul extant stock price cgen one small-mid cap player
tigit space believ incorpor acquisit premium valuat warrant
use refer median take-over premium paid
larg pharma biopharma target
note appli premium current
cgen price averag calcul npv blend would
give us price target
meaning data catalyst cgen year away expect stock
trade near term gener sentiment around tigit
use
remov data roch
disappoint broadli
target tigit
premium appli
take-over premium appli
biopharma acquisit last
decad transact
valu blend
discount cash flow
multipl pipelin asset
nol
believ broad interest
tigit fuel roch
confid target
decis evalu
random data asco
support roch
premium appli
premium seen biopharma
acquisit
market cap space
acquisit peer
increas presum valu
close
tigit pvrig could next evolut immun checkpoint blockad valu
compugen perspect co-discov pathway although anti-tigit landscap
becom increasingli crowd compugen pursu uniqu strategi inspir
decad long work axi signal block tigit pvrig relat immun checkpoint
receptor signal parallel compani hypothesi import target
pvrig certain indic proven correct compugen would enviabl posit
pvrig program clinic develop
compugen scarciti valu smid compani activ pvrig/tigit
program gener clinic data data anti-pvirg present
modest promis smid competitor major catalyst class
horizon believ cgen attract target
lean oper structur strong cash balanc provid good runway compugen
well capit come recent financ fund estim suffici support
oper
cgen valuat risk valuat
price target base blend dcf multiples-bas analysi simul revenu
anticip loss exclus cgen oncolog asset use discount rate
account net cash also add premium deriv analysi transact
past decad reflect continu specul enthusiasm ahead valid competitor
catalyst project revenu gener rang outcom
deriv ionian mont carlo simul io industri pipelin
risk valuat
near-term readout roch disappoint investor enthusiasm tigit pvrig like
compugen asset could sub-par efficaci safeti profil rel competit program
fc-fcr engag prove benefici efficaci human compugen choic
backbon anti-tigit poor one dual pvrig tigit antagon may prove
insuffici unnecessari especi tigit uniqu mechan drive clinic efficaci
absenc partner acquir compugen could struggl complet clinic deep-
pocket rival multi-year clinic lead
presid
presid
dr cohen-dayag join cgen held variou posit novemb dr cohen-dayag
appoint vice-president research develop june dr cohen-dayag appoint co-chief
execut offic cgen march dr cohen-dayag appoint compugen presid
ceo dr cohen-dayag join compugen board director prior join cgen dr cohen-dayag
head member execut manag mindsens biosystem prior dr cohen-
dayag serv scientist depart orgen dr cohen-dayag hold sc biolog
ben-gurion univers sc chemic immunolog ph cellular biolog
weizmann institut scienc addit dr cohen-dayag director iati isra advanc
mr krashin join cfo compugen appoint also mr krashin
year experi capit market financ busi develop serv chief financi offic
public privat compani recent anyclip media spacenet inc mr krashin
certifi public account began profession career kesselman kesselman pwc israel mr
krashin hold busi administr account colleg manag rishon lezion
dr adewoy join cgen march chief medic offic bring year extens experi
lead multipl clinic trial oncolog hematolog biopharmaceut industri
academia compugen dr adewoy clinic director oncolog
clinic research oncolog leadership previous clinic research medic
director oncolog amgen inc dr adewoy complet fellowship hematology/oncolog boston
medic center complet resid intern medicin meharri medic colleg dr adewoy
receiv medic degre univers jo nigeria fellowship train hematolog
laboratori medicin univers colleg hospit ibadan nigeria dr adewoy board certifi
american board intern medicin medic oncolog hematolog intern medicin
corpor
dr froeschei join cgen januari senior vice presid busi corpor develop dr
froeschei bring compugen year experi pharmaceut industri held
posit research project manag market busi develop dr froeschei join cgen
roch spent last year partner organ initi serv global due
dilig director in-licens project act director busi develop
licens respons oncology/immuno-oncolog partner project recent lead out-
licens across therapeut area dr froeschei hold diploma chemistri ph analyt
chemistri univers ulm germani
ip manufactur
feb cgen issu allow patent includ us europ elsewher
addit compani pend patent applic file territori world-wide
patent issu us eu cover composit method combin
checkpoint set expir earlier
cgen manufactur facil reli contract manufactur produc drug materi
object interpret result single-arm combin trial
oncolog inspir riba propos
threshold requir posit early-stag signal
set
ppt orr patient
promis result larger size need verifi
set
activ
set
ppt orr less patient
ppt delta orr patient
ppt delta orr less patient
ppt delta orr patient
ppt delta orr
proof concept poc fabul signal move aggress registration-en trial
promis intrigu signal confirm signal increas patient number and/or random phase data
poor signal littl evid efficaci project discontinu
also depriorit unaccept toxic pazopanib rcc random os need demonstr combin synergist synergist
sequenc may prefer given toxic expens antoni riba note sourc may requir subscript
